Company
Sumitomo Pharma
Sumitomo Pharma has 41 drugs tracked on RxWires: 5 post-market, 14 in Phase 3, 1 in Phase 2/3, 4 in Phase 2, 7 in Phase 1/2, 9 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Lunesta | Post-Market | Poor Quality Sleep |
| Eszopiclone | Post-Market | Sleep Initiation and Maintenance Disorders |
| Racemic albuterol (R+S albuterol) | Post-Market | Asthma |
| nebulized albuterol (2.5 mg/3ml/dose) | Post-Market | Mucociliary Clearance |
| Lurasidone | Post-Market | Schizophrenia |
| Amrubicin Hydrochloride | Phase 3 | Small-cell Lung Cancer |
| levalbuterol | Phase 3 | Asthma |
| Lurasidone HC1 | Phase 3 | Chronic Schizophrenia |
| APL-130277 | Phase 3 | Motor OFF Episodes Associated With Parkinson's Disease |
| Napabucasin | Phase 3 | Carcinoma, Non-Small-Cell Lung |
| Arformoterol tartrate inhalation solution | Phase 3 | Chronic Obstructive Pulmonary Disease |
| Levalbuterol tartrate HFA MDI | Phase 3 | Exercise-induced Bronchospasm |
| Arformoterol | Phase 3 | Chronic Obstructive Pulmonary Disease |
| SM-13496 | Phase 3 | Schizophrenia |
| Amrubicin hydrocloride | Phase 3 | Lung Cancer |
| Relugolix Combination Therapy | Phase 3 | Contraception |
| DSP-7888 Dosing Emulsion | Phase 3 | Glioblastoma |
| Lurasidone 20, 40, 60, 80 mg, flexibly dosed | Phase 3 | Schizophrenia |
| Relugolix | Phase 3 | Prostate Cancer |
| SEP-363856 50 mg | Phase 2/3 | Schizophrenia |
| SEP-225289 | Phase 2 | Adult Attention Deficit Hyperactivity Disorder |
| BBI608 | Phase 2 | Colorectal Cancer |
| BBI503 | Phase 2 | Cancer |
| Alvocidib | Phase 2 | Acute Myeloid Leukemia |
| DSP-3077 Retinal Sheet Cohort 1 | Phase 1/2 | Retinitis Pigmentosa |
| Cultured Thymus Tissue for Implantation (CTTI) | Phase 1/2 | DiGeorge Anomaly |
| DSP-1083 implantation | Phase 1/2 | Parkinson's Disease |
| Enzomenib | Phase 1/2 | Leukemia, Myeloid, Acute |
| Nusivertib | Phase 1/2 | Myelofibrosis |
| SMP3124LP | Phase 1/2 | Solid Tumor |
| DSP-0509 | Phase 1/2 | Neoplasms |
| DSP-0390 | Phase 1 | Small-cell Lung Cancer |
| WT2725 | Phase 1 | Cancer |
| DSP-1349M | Phase 1 | Schizophrenia |
| dasotraline | Phase 1 | Attention Deficit Hyperactivity Disorder (ADHD) |
| DSP-8658 | Phase 1 | Type 2 Diabetes Mellitus |
| TP-3654 | Phase 1 | Myelofibroses |
| DSP-5336 | Phase 1 | Advanced Hematologic Malignancies |
| DSP-0337 | Phase 1 | Neoplasms |
| fH1 2 ug | Phase 1 | Influenza |
| ipratropium | Not Applicable | Asthma |
Latest
Follow Sumitomo Pharma on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.